Jefferies assigned a Buy rating to Anthem Biosciences with a target price of Rs 1,050, projecting 19% EPS CAGR over FY26-29. Jefferies said Anthem Biosciences stands out for specialised manufacturing in fermentation, biotransformation, complex peptides, flow chemistry and oligonucleotides, with $31.2 billion in associated end-market sales.

Anthem Biosciences was the subject of a Rs 249.90 crore BSE block deal on October 9 after Portsmouth Technologies LLC sold 30 lakh shares at Rs 833 per share, representing about 19.49% of Portsmouth's 2.73% holding as of June 30, 2026. The transaction was priced about 3.29% below Anthem Biosciences' Rs 861.35 closing price.